Cytek Biosciences, Inc.
CTKB Nasdaq· Laboratory Analytical Instruments
Last close · Oct 23, 2026
$5.59
KIRA · Stoqly’s AI analyst, in plain words
- Cytek Biosciences, Inc. had $201M of revenue in fiscal 2025, up 0.5% on the year before. Over five years, revenue changed +209.5% a year on average.
- Its operating margin was −20.0%, down 9.8 pts: of every 100 in sales, about −20 is left after running the business.
- Cytek Biosciences, Inc. lost $66.5M in fiscal 2025.
- Free cash flow was −$8.8M in fiscal 2025, −4.4% of revenue.
- Cytek Biosciences, Inc. returned $15.1M to shareholders in fiscal 2025. The diluted share count fell 2.2%.
Market cap
$724M
P/E
—
Revenue
$201M
Net income
−$66.5M
Free cash flow
−$8.8M
Operating margin
−20.0%
Cytek Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+0.5%
Only a little. Sales grew 0.5% last year.
Does it make a profit?
−33.0%
No. It lost money last year.
Does profit turn into cash?
−4.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
What Cytek Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Cytek Biosciences, Inc.
- CIK
- 0001831915
Cytek Biosciences, Inc. · CTKB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.2M | $3.0M | $193M | $200M | $201M |
| Revenue growth | 207.2% | 35.9% | 6,414.2% | 3.9% | 0.5% |
| Gross margin | 3,628.8% | 3,407.8% | 56.7% | 55.4% | 51.8% |
| Operating margin | 419.9% | −60.9% | −14.4% | −10.2% | −20.0% |
| Net income | $3.0M | $2.5M | −$12.1M | −$6.0M | −$66.5M |
| Net margin | 138.8% | 83.8% | −6.3% | −3.0% | −33.0% |
| Diluted EPS | $0.00 | $0.02 | −$0.09 | — | — |
| Cash | |||||
| Cash from operations | $4.6M | −$12.2M | $5.3M | $25.4M | −$4.7M |
| Capital expenditure | $4.4M | $9.7M | $4.6M | $3.5M | $4.1M |
| Free cash flow | $0.3M | −$22.0M | $0.6M | $21.9M | −$8.8M |
| FCF margin | 12.2% | −741.8% | 0.3% | 10.9% | −4.4% |
| Share buybacks | $0.0M | $0.0M | $44.2M | $21.6M | $15.1M |
| Share count change | 150.1% | 69.9% | −2.4% | −3.5% | −2.2% |
| Debt and strength | |||||
| Cash and short-term investments | $365M | $297M | $167M | $98.7M | $90.9M |
| Shareholders' equity | $405M | $426M | $393M | $396M | $342M |
| Current ratio | 13.0x | 9.3x | 7.0x | 5.9x | 5.0x |
| Interest coverage | 5.3x | −0.7x | −13.4x | — | −85.2x |
| Returns and quality | |||||
| Return on equity | 1.6% | 0.6% | −3.0% | −1.5% | −18.0% |
| Return on tangible equity | 0.0% | 0.6% | −3.4% | −1.7% | −21.6% |
| Piotroski F-score | 5 | 2 | 4 | 5 | 3 |
| Altman Z'' | 13.0 | 9.7 | 8.0 | 7.8 | 6.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cytek Biosciences, Inc. · CTKB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.59 a share, the company is worth $724M.
Source: SEC EDGAR XBRL filings (CIK 0001831915). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.